Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 14, 2019; 25(22): 2809-2818
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2809
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2809
Table 3 Treatment regimens
Author (year) | Treatments |
Schramm et al[6], 2001 | P 1 mg/kg/die |
P 1 mg/kg/die + AZA 1-1.5 mg/kg/die | |
No treatment | |
Granito et al[21], 2005 | M 1 mg/kg/die |
M 30 mg/die + AZA 50 mg/die | |
No treatment | |
Al-Chalabi et al[23], 2006 | P 20-40 mg/die |
P 20-40 mg/die + AZA (1 mg/kg/die) | |
P 20-40 mg/die + Cyclo (only in the younger group) | |
P 20-40 mg/die + D-P (only in the younger group) | |
Czaja et al[9], 2006 | Pp (doses not specified) |
Pp + AZA (doses not specified) | |
Investigational therapies (drugs not specified) | |
No Treatment | |
Zhang et al[22], 2012 | P (doses not specified) |
P + AZA (doses not specified) | |
No treatment | |
Zachou et al[20], 2016 | P 0,5-1 mg/kg/die + MMF 1.5-2g/die |
P 0,5-1 mg/kg/die | |
P 0.5-1 mg/kg/die + AZA 1.5-2 mg/kg/die | |
Morii et al[24], 2017 | Pp 30-40 mg/die |
UDCA (dose not specified) |
- Citation: Durazzo M, Lupi G, Scandella M, Ferro A, Gruden G. Autoimmune hepatitis treatment in the elderly: A systematic review. World J Gastroenterol 2019; 25(22): 2809-2818
- URL: https://www.wjgnet.com/1007-9327/full/v25/i22/2809.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i22.2809